Anti-IL6R role in treatment of COVID-19-related ARDS

Anti-IL6R role in treatment of COVID-19-related ARDS

Bibliographic Details
Main Authors:	Franco Maria Buonaguro, Igor Puzanov, Paolo Antonio Ascierto
Format:	Article
Language:	English
Published:	BMC 2020-04-01
Series:	Journal of Translational Medicine
Subjects:	COVID-19 SARS-CoV-2 ARDS IL-6 Tocilizumab
Online Access:	http://link.springer.com/article/10.1186/s12967-020-02333-9

Similar Items

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
by: Corrado Pelaia, et al.
Published: (2021-03-01)

Association of Polymorphisms of IL-6 Pathway Genes (IL6, IL6R and IL6ST) with COVID-19 Severity in an Amazonian Population
by: Fabíola Brasil Barbosa Rodrigues, et al.
Published: (2023-05-01)

The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
by: Avi Gurion Kaye, et al.
Published: (2020-11-01)

Why tocilizumab could be an effective treatment for severe COVID-19?
by: Binqing Fu, et al.
Published: (2020-04-01)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
by: Robert Flisiak, et al.
Published: (2021-04-01)

A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages
by: Maaike C. Swets, et al.
Published: (2023-04-01)

How to follow-up a patient who received tocilizumab in severe COVID-19: a case report
by: Regina B. Podlasin, et al.
Published: (2020-08-01)

Biopharmaceutical Assessment of Mesh Aerosolised Plasminogen, a Step towards ARDS Treatment
by: Lucia Vizzoni, et al.
Published: (2023-05-01)

IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome
by: Etienne Dufranc, et al.
Published: (2020-04-01)

Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study
by: Jing Zhang, et al.
Published: (2020-10-01)

Successful use of VA-ECMO in the treatment of an infant with SARS-CoV-2 associated ARDS: A case experience of China and literature review
by: Yi-Rong Zheng, et al.
Published: (2023-01-01)

Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials
by: Tarun Krishna Boppana, et al.
Published: (2022-02-01)

Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6
by: Pan Li, et al.
Published: (2021-04-01)

Multimodality treatment in immunocompromised patients with severe COVID‐19: the role of IL‐6 inhibitor, intravenous immunoglobulin, and haemoperfusion
by: Nophol Leelayuwatanakul, et al.
Published: (2021-04-01)

Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
by: Nicola Potere, et al.
Published: (2020-11-01)

Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients
by: Raffaella Marocco, et al.
Published: (2022-04-01)

Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome
by: Reid Rubsamen, et al.
Published: (2020-09-01)

Subphenotypes of SARS-CoV-2-Associated ARDS Overlap Each Other: A Retrospective Analysis
by: Parvathy R. Nair, et al.
Published: (2023-12-01)

Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance
by: Gaetano Scaramuzzo, et al.
Published: (2023-03-01)

Effects of tocilizumab and dexamethasone on the downregulation of proinflammatory cytokines and upregulation of antioxidants in the lungs in oleic acid-induced ARDS
by: Funda Terzi, et al.
Published: (2022-09-01)

Acute Cor Pulmonale in COVID-19-Related ARDS
by: Pierre Huette, MD, et al.
Published: (2020-07-01)

Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial
by: Maria Boesing, et al.
Published: (2022-09-01)

Pathogenesis of IL-6 and potential therapeutic of IFN-γ in COVID-19
by: Ahmed Hasan Mohammed
Published: (2020-08-01)

Addition of Tocilizumab to the Standard of Care Reduces Mortality in Severe COVID-19: A Systematic Review and Meta-Analysis
by: Umesha Boregowda, et al.
Published: (2020-10-01)

A Case of COVID-19 with Acute Exacerbation after Anti-Inflammatory Treatment
by: Yugo Ashino, et al.
Published: (2022-06-01)

Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation
by: Francesco Menzella, et al.
Published: (2020-09-01)

Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS
by: Zhiheng Xu, et al.
Published: (2021-10-01)

IL-6 Inhibition in Critically Ill COVID-19 Patients Is Associated With Increased Secondary Infections
by: Lucas M. Kimmig, et al.
Published: (2020-10-01)

Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia
by: Daria Fomina, et al.
Published: (2020-10-01)

Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation during Acute Respiratory Distress: A Case Report and Literature Review
by: Faryal Farooqi, et al.
Published: (2020-07-01)

Anti-IL6 Autoantibodies in an Infant With CRP-Less Septic Shock
by: Marketa Bloomfield, et al.
Published: (2019-11-01)

Effects of IL-6 Signaling Pathway Inhibition on Weight and BMI: A Systematic Review and Meta-Analysis
by: Olivia Patsalos, et al.
Published: (2020-08-01)

IL‐6 receptor blockade for allograft dysfunction after lung transplantation in a patient with COPA syndrome
by: Peter Riddell, et al.
Published: (2021-01-01)

The Prevalence of Acute Respiratory Distress Syndrome (ARDS) and Outcomes in Hospitalized Patients with COVID-19—A Study Based on Data from the Polish National Hospital Register
by: Mariusz Gujski, et al.
Published: (2022-01-01)

Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study
by: Anna Olewicz-Gawlik, et al.
Published: (2021-12-01)

Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study
by: Wael Hafez, et al.
Published: (2022-02-01)

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study
by: Tariq Kewan, et al.
Published: (2020-07-01)

SARS-CoV-2 Viremia Precedes an IL6 Response in Severe COVID-19 Patients: Results of a Longitudinal Prospective Cohort
by: Emilia Roy-Vallejo, et al.
Published: (2022-06-01)

TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling
by: Gali Epstein Shochet, et al.
Published: (2020-02-01)

IL-10/IL-6 ratio from nasal & oral swab samples, acts as an inflammatory indicator for COVID-19 patients infected with the delta variant
by: Biswajit Biswas, et al.
Published: (2023-06-01)